 |
 |
 |
 |
 |
 |
  |
Board ObserversCharles Fong |
LeadershipManagement Team |
Suman Rakhit, PhD, CSO, NeurAxon Inc. Founder and CEO of MCR Research Inc. a medicinal chemistry CRO. Former Director of the Medicinal Chemistry at Allelix Biopharmaceuticals and BioMega-Boehringher Ingelheim. More than 37 years experience in drug discovery and development. Co-discovered Rapamycin, an anti-rejection drug, at Ayerst Laboratories. Discovered anti-migraine drug ALX-646, an antimigraine drug currently undergoing Phase 2 clinical trials by Allelix. Responsible for the dopaminergic antagonist program for the treatment of Schizophrenia which was licensed to Aventis for over C$50 million in 1995. Part of a team which established Bio-Mega and its research programs, eventually acquired by Boehringer-Ingelheim. More than 70 publications and 25 patents in synthetic chemistry and lead optimization. |
|